Skip to main content

Table 2 Transplant outcomes between patients who underwent Haplo-SCT and those who received MSDT

From: Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study

ParameterHaplo-SCT group (n = 169)MSDT group (n = 39)P value
Median time of neutrophil engraftment (range)13 days (10–25 days)15 days (9–22 days)0.016
Platelet engraftment at day 100 post-transplantation95% (95% CI, 92–98%)100%< 0.001
CMV reactivation at day 100 post-transplantation68% (95% CI, 61–75%)18% (95% CI, 6–30%)< 0.001
EBV reactivation at day 100 post-transplantation15% (95% CI, 10–21%)00.011
Grades II–IV acute GVHD21% (95% CI, 17–27%)23% (95% CI, 10–36%)0.884
Total chronic GVHD44% (95% CI, 36–52%)48% (95% CI, 31–65%)0.850
Moderate-to-severe chronic GVHD18% (95% CI, 10–26%)27% (95% CI, 10–44%)0.192
Cumulative incidence of positive MRD after transplantation26% (95% CI, 19–33%)44% (95% CI, 28–60%)0.043
Three-year probability of relapse23% (95% CI, 17–29%)47% (95% CI, 31–63%)0.006
Three-year probability of NRM11% (95% CI, 6–16%)10% (95% CI, 1–19%)0.845
Three-year probability of LFS65% (95% CI, 58–72%)43% (95% CI, 27–59%)0.023
Three-year probability of OS68% (95% CI, 61–75%)46% (95% CI, 30–62%)0.039
Three-year probability of GRFS54% (95% CI, 46–62%)36% (95% CI, 21–51%)0.055
  1. Haplo-SCT haploidentical stem cell transplantation, MSDT human leukocyte antigen-matched sibling donor transplantation, CI confidence interval, GVHD graft-versus-host disease, MRD measurable residual disease, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival